Acrivon Therapeutics, Inc.
ACRV
$1.52
-$0.06-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.12% | 13.20% | -6.74% | 13.80% | -1.74% |
| Total Depreciation and Amortization | 3.44% | 4.18% | 7.72% | 2.64% | 20.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.72% | 3.17% | 8.97% | 20.50% | 12.95% |
| Change in Net Operating Assets | -106.75% | 2,719.23% | 101.35% | -281.80% | -2.26% |
| Cash from Operations | -24.05% | 26.05% | 14.97% | -12.53% | -0.21% |
| Capital Expenditure | 75.64% | -82.35% | -750.00% | 92.99% | 16.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 219.28% | -65.85% | 3.49% | 26.46% | -10.36% |
| Cash from Investing | 264.13% | -69.61% | 1.23% | 33.32% | -9.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -64.10% | -20.62% | 71.80% | 46.83% | 45.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -64.10% | -20.62% | 71.72% | 46.99% | 56.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 193.93% | -336.48% | 513.25% | 81.53% | -27.66% |